CMOTEC_B: Strong Q3 revenue growth and record Animal Care sales drive improved financials and outlook

About this update from Scandinavian Chemotech Ab Class B

Q3 2025 saw strong revenue growth, improved profitability, and record Animal Care sales, with the U.S. market driving expansion. The company raised new capital, continues to invest in R&D, and aims for cash flow positivity by year-end despite ongoing funding needs.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Scandinavian Chemotech Ab Class B